Position of the Transparency Council – Remsima (infliximab)

At its meeting on 24 February 2025, the Transparency Council adopted position No. 24/2025 on the evaluation of the drug Remsima (infliximab) under the drug program B.35. “Treatment of patients with psoriatic arthritis (PsA) (ICD-10: L40.5, M07.1, M07.2, M07.3)”

Publication of the position >>